Visualization of Protein-Drug Interactions for the Analysis of Drug Resistance in Lung Cancer

Non-small cell lung cancer (NSCLC) caused by mutation of the epidermal growth factor receptor (EGFR) is a major cause of death worldwide. Tyrosine kinase inhibitors (TKIs) of EGFR have been developed and show promising results at the initial stage of therapy. However, in most cases, their efficacy becomes limited due to the emergence of secondary mutations causing drug resistance after about a year. In this work, we investigated the mechanism of drug resistance due to these mutations. We performed molecular dynamics (MD) simulations of EGFR-drug interactions to obtain Euclidean distance and binding free energy values to analyse drug resistance and visualize drug-protein interactions. A PCA-based method is proposed to find normal, rigid, flexible, and critical residues. We have established a systematic method for the visualization of protein-drug interactions, which provides an effective framework for the analysis of drug resistance in lung cancer at the atomic level.

[1]  Haruki Nakamura,et al.  Announcing the worldwide Protein Data Bank , 2003, Nature Structural Biology.

[2]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[3]  Daniel R Roe,et al.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.

[4]  Hong Yan,et al.  Hydrogen bond analysis of the EGFR-ErbB3 heterodimer related to non-small cell lung cancer and drug resistance. , 2019, Journal of theoretical biology.

[5]  Xin-Qiu Yao,et al.  Comparative Protein Structure Analysis with Bio3D-Web. , 2020, Methods in molecular biology.

[6]  Arvind Ramanathan,et al.  An Online Approach for Mining Collective Behaviors from Molecular Dynamics Simulations , 2009, RECOMB.

[7]  D. Eisenberg,et al.  VERIFY3D: assessment of protein models with three-dimensional profiles. , 1997, Methods in enzymology.

[8]  Hong Yan,et al.  Parametric Models for Understanding Atomic Trajectories in Different Domains of Lung Cancer Causing Protein , 2019, IEEE Access.

[9]  Stephen T. C. Wong,et al.  Optimal Drug Prediction From Personal Genomics Profiles , 2015, IEEE Journal of Biomedical and Health Informatics.

[10]  Chee-Keong Kwoh,et al.  Ensemble Prediction of Synergistic Drug Combinations Incorporating Biological, Chemical, Pharmacological, and Network Knowledge , 2019, IEEE Journal of Biomedical and Health Informatics.

[11]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[12]  Peter M. A. Sloot,et al.  Multi-scale modelling in computational biomedicine , 2010, Briefings Bioinform..

[13]  Hong Yan,et al.  Computational Evaluation of EGFR Dynamic Characteristics in Mutation-Induced Drug Resistance Prediction , 2015, 2015 IEEE International Conference on Systems, Man, and Cybernetics.

[14]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[15]  C. Lovly,et al.  Mechanisms of receptor tyrosine kinase activation in cancer , 2018, Molecular Cancer.

[16]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Hai Hu,et al.  PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B , 2019, Scientific Reports.

[18]  Charu Aggarwal,et al.  Targeted therapy for lung cancer: present and future. , 2014, Annals of palliative medicine.

[19]  C. Borchers,et al.  Protein unfolding as a switch from self-recognition to high-affinity client binding , 2016, Nature Communications.

[20]  A. Datta,et al.  Cryptotanshinone Induces Cell Death in Lung Cancer by Targeting Aberrant Feedback Loops , 2019, IEEE Journal of Biomedical and Health Informatics.

[21]  Hong Yan,et al.  Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics , 2016, Proteome Science.

[22]  Valerio Persico,et al.  Big Data for Health , 2019, Encyclopedia of Big Data Technologies.

[23]  Eduard Batlle,et al.  Metastatic stem cells: sources, niches, and vital pathways. , 2014, Cell stem cell.

[24]  Jonathon Shlens,et al.  A Tutorial on Principal Component Analysis , 2014, ArXiv.

[25]  Khurram Khurshid,et al.  Multistage Adaptive filter for ECG signal processing , 2017, 2017 International Conference on Communication, Computing and Digital Systems (C-CODE).

[26]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[27]  Lijiang Chen,et al.  Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations , 2017, Scientific Reports.

[28]  R. Harris,et al.  Autocrine, paracrine and juxtacrine signaling by EGFR ligands. , 2005, Cellular signalling.

[29]  Simona Distinto,et al.  Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—What can we learn from earlier mistakes? , 2008, J. Comput. Aided Mol. Des..

[30]  M. Provencio,et al.  Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. , 2012, Cancer treatment reviews.

[31]  S. Khozin,et al.  U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. , 2014, The oncologist.

[32]  Harun Patel,et al.  Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. , 2017, European journal of medicinal chemistry.

[33]  Thomas Blaschke,et al.  The rise of deep learning in drug discovery. , 2018, Drug discovery today.

[34]  Hong Yan,et al.  Computational Analysis of Structural Dynamics of EGFR and its Mutants , 2019, 2019 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).

[35]  Masahiko Ando,et al.  Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Dan Cheng,et al.  MULTIPLE TESTING OF LOCAL MAXIMA FOR DETECTION OF PEAKS IN RANDOM FIELDS. , 2014, Annals of statistics.

[37]  David Baker,et al.  Protein Structure Prediction Using Rosetta , 2004, Numerical Computer Methods, Part D.

[38]  Benjamin Haibe-Kains,et al.  Machine learning approaches to drug response prediction: challenges and recent progress , 2020, npj Precision Oncology.

[39]  Sangdun Choi,et al.  Structure-Activity Relationship in TLR4 Mutations: Atomistic Molecular Dynamics Simulations and Residue Interaction Network Analysis , 2017, Scientific Reports.

[40]  Hong Yan,et al.  Personalized prediction of EGFR mutation-induced drug resistance in lung cancer , 2013, Scientific Reports.

[41]  Hong Yan,et al.  EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib , 2015, BMC Bioinformatics.

[42]  Amarpal Singh,et al.  Z-SCORE FOR HOMOLOGY MODELING AND STRUCTURE PREDICTION OF GLOBULAR PROTEIN OF HOMOSAPIENS & PLANT , 2013 .

[43]  Surjit B. Dixit,et al.  Root Mean Square Deviation Probability Analysis of Molecular Dynamics Trajectories on DNA , 2006, J. Chem. Inf. Model..

[44]  Hong Yan,et al.  Predicting the impacts of mutations on protein-ligand binding affinity based on molecular dynamics simulations and machine learning methods , 2020, Computational and structural biotechnology journal.

[45]  Rohit Shukla,et al.  Distant Phe345 mutation compromises the stability and activity of Mycobacterium tuberculosis isocitrate lyase by modulating its structural flexibility , 2017, Scientific Reports.

[46]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[47]  Hong Yan,et al.  Correlated Motions and Dynamics in Different Domains of Epidermal Growth Factor Receptor With L858R and T790M Mutations , 2020, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[48]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[49]  Chee Kheong Siew,et al.  Extreme learning machine: Theory and applications , 2006, Neurocomputing.

[50]  Syed Sibte Raza Abidi,et al.  A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer , 2016, IEEE Journal of Biomedical and Health Informatics.